ALZN (2.65) liking the risk/reward at these low levels. Surprised that it's still lingering at such beaten down prices even after the good news on Sept 30. Also had a PT upgrade to $8 since then. Key points of note:
FDA pre-IND response for their cell-based therapeutic vaccine to restore patients' immunological system to combat Alzheimer's disease
The FDA agreed to Alzamend's proposed combined Phase 1/2 study
Alzamend will file the IND by the end of November and initiate the clinical trial of AL002 in Q1 of 2022.
Market Data 
Markets 
AI
